What did the retatrutide TRIUMPH-2 results actually show, and is retatrutide legal to buy?
Short answer · as of 2026-10-06
DOCUMENTED. Lilly’s release of Sept. 29, 2026 reports 20.8% average weight loss at the 12 mg dose (efficacy estimand) over 80 weeks in adults with obesity and type 2 diabetes, against 4.0% with placebo. Lilly calls retatrutide an investigational molecule that cannot be legally sold or marketed for human use.
Attribution: Compiled from Lilly’s release and AJMC’s report, read on October 6, 2026. The Lancet paper returned an access error and was not read. Figures are the sponsor’s and describe trial participants on treatment, not a recommended regimen.
What happened
Lilly announced detailed TRIUMPH-2 results on Sept. 29, 2026. The trial studied retatrutide in adults with obesity and type 2 diabetes. AJMC reports the paper was published in The Lancet with a presentation at the European Association for the Study of Diabetes meeting, dated Sept. 30.
On the efficacy estimand, average weight loss was 12.7% at 4 mg, 19.1% at 9 mg and 20.8% at 12 mg, against 4.0% on placebo. Lilly reports that 10.8%, 30.6% and 34.9% of participants lost 25% or more, against 0.8% on placebo. AJMC adds 23.4% average loss among participants with a baseline BMI of 35 or higher at 12 mg.
A1C fell by an average of 1.4% (4 mg), 1.6% (9 mg) and 1.5% (12 mg), against 0.2% on placebo. Discontinuation for adverse events was 3.8%, 11.6% and 7.7% by dose, against 4.9% on placebo.
Lilly says it plans to submit a biologics license application in the first quarter of 2027.
What we can verify
- The weight, A1C, side-effect and discontinuation figures above appear in Lilly’s release as we read it. AJMC repeats the efficacy-estimand average (20.8% at 12 mg) and the diarrhea and discontinuation ranges.
- The statement that retatrutide is investigational and cannot be legally sold or marketed for human use is Lilly’s.
What remains unknown
- The Lancet paper itself, including enrollment: it returned an access error. Another summary circulating gives a lower 12 mg average (18.8%); we could not tie it to a source. A treatment-regimen estimand would typically be lower than the efficacy estimand reported here.
- Long-term safety beyond the 80-week trial.
- When, or whether, FDA will approve retatrutide.
Timeline
| Date / time | Event |
|---|---|
| 2026-09-29 | Lilly publishes detailed TRIUMPH-2 results. |
| 2026-09-30 | AJMC reports publication in The Lancet alongside an EASD presentation. |
| 2027 Q1 (planned) | Lilly says it plans a biologics license application submission. |
Receipts
- Lilly: retatrutide delivered substantial weight loss and A1C reduction in obesity with type 2 diabetes (Sept. 29, 2026)
- AJMC: Retatrutide yields up to 20.8% weight loss in obesity with T2D
- The Lancet: Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) (abstract; not read, access error)
Company response
No company response located as of the publish date.
Why people care
Retatrutide is among the most-searched peptides, and sellers of unapproved versions are named in several records on this site. The trial shows what the sponsor reported under study conditions; Lilly itself says the drug cannot be legally sold.
Common questions
Did retatrutide cause 25% average weight loss?
No. Lilly reports 20.8% average weight loss at the 12 mg dose on the efficacy estimand, against 4.0% on placebo. A separate figure says 34.9% of participants at that dose lost 25% or more. An average and a share of participants are different measures.
Does retatrutide cause abnormal skin sensations?
Lilly reports dysesthesia in 4.5% to 7.3% of participants across retatrutide doses, against 0.7% on placebo, in this trial.
Is retatrutide legal to buy?
Lilly says retatrutide is an investigational molecule that cannot be legally sold or marketed for human use, and that it plans to submit an application in the first quarter of 2027. Products sold now as retatrutide are not approved drugs.
What does TRIUMPH-2 mean for people using retatrutide from other sellers?
The trial gave participants study drug under protocol. Its results do not describe products sold elsewhere. This is not medical advice; talk to a licensed clinician.
Corrections and update log
No corrections or updates. Request a correction.